Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.40 |
| ▸ | PAM | P19021 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669706 | 0.79 | CES1 (0.56) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL18327104 | 0.79 | CES1 (0.47) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL11058375 | 0.78 | CES1 (0.40) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL15777894 | 0.78 | CES1 (0.54) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL8825672 | 0.78 | CES1 (0.54) | CES1CES2AKR1B1MEN1KMT2A | |
| Ammonia Solution, Strong SCHEMBL11111905 | 0.78 | CES1 (0.54) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL28172331 | 0.78 | CES1 (0.54) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL1245524 | 0.76 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| Oxalic Acid SCHEMBL29268820 | 0.76 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A | |
| SCHEMBL11810722 | 0.76 | CES1 (0.52) | CES1CES2AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524744-B2 | preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc. | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2013-09-03 | — | — | US | disclosed |
| US-20080221106-A1 | Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use | INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2008-09-11 | — | — | US | disclosed |
| EP-1783115-A1 | ARYLAMINE KETONES, THEIR PREPARATION METHODS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE | INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221106-A1 | Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use | AHR, KYNU, AADAC | CES1 555/4885CES2 4241/4885AKR1B1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.